U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children

PipelineReview.com

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) to include children 6 weeks through 17 years of age. VAXNEUVANCE is now indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.

Latest articles

Carla Peeters A lingering disorder that can last for months or years...
el gato malo … the CDC just dramatically changed their claims about...
Meryl Nass Just like the COVID vaccines, turns out that in the...
Joseph Mercola The COVID-19 vaccine is causing AIDS-like immunodepression, which helps create...
Kiwako Yamamoto-Hanada et al. Adjuvants used in inactivated vaccines often upregulate type...

Your donation helps us
stand up for health freedom!

Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.

Stay up to date

Sign up to our newsletter to get the latest health-related news and events delivered straight to your inbox.

Become a CHA member

Become an active value-added member and trusted provider of medical and healthcare information and education by joining the CHA Membership Program.

Your donation helps us stand up for healthcare choice!

Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.

Thank you!